Evaluation of irritation potential of topical formulations on intact skin

2024-511826-29-00 Protocol LT_EUR_MOME/2023 Human pharmacology (Phase I) - Other Ended

Start 20 Jun 2024 · End 22 Jul 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol LT_EUR_MOME/2023

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 33
Countries 1
Sites 1

Dermal tolerability test: Testing for non-specific, local irritating reactions on intact skin using mean cumulative irritation score (CIS).

Key facts

Sponsor
Grindeks AS
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Phenomena and Processes [G] - Cell Physiological Phenomena [G04], Phenomena and Processes [G] - Physiological processes [G07]
Trial duration
20 Jun 2024 → 22 Jul 2024
Decision date (initial)
2024-06-07
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Dermal tolerability test: Testing for non-specific, local irritating reactions on intact skin using mean cumulative irritation score (CIS).

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Grindeks AS

Sponsor organisation
Grindeks AS
Address
Krustpils Iela 53
City
Riga
Postcode
1057
Country
Latvia

Scientific contact point

Organisation
Grindeks AS
Contact name
Head of Drug Research and Intellectual Property Group

Public contact point

Organisation
Grindeks AS
Contact name
Head of Drug Research and Intellectual Property Group

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 33 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Eurofins bioskin GmbH
Research Center Dermatology, Messberg 4, Hamburg-Altstadt, Hamburg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-06-20 2024-07-22 2024-06-26 2024-07-01

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-27 Germany Acceptable
2024-06-06
2024-06-07